Prelude Therapeutics Inc (PRLD) company profile

Prelude Therapeutics Incorporated is a clinical-stage precision oncology biopharmaceutical company focused on discovering and developing targeted cancer therapies. The company identifies compelling biological target mechanisms, such as transcriptional regulation and cell proliferation signaling pathways, to design new chemical entities. Its product candidate pipeline utilizes multiple therapeutic modalities, including small-molecule inhibitors, targeted protein degraders, and precision antibody-drug conjugates. Prelude focuses its development programs on underserved patient populations with solid tumors and hematological malignancies that have high unmet medical needs. Key programs include lead candidates such as PRT12396, a selective JAK2 inhibitor, and preclinical candidates targeting KAT6A as well as mutated calreticulin.

The company operates primarily in the United States and conducts its research and clinical development activities domestically. Prelude conducts corporate operations from its principal executive offices and headquarters located in Wilmington, Delaware. It also collaborates with external biopharmaceutical partners to discover, develop, and commercialize novel degrader antibody conjugate programs.

Summary of the business section of Prelude Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 79 full-time employees.”